Abstract:Alzheimer's disease (AD) is the most common form of neurodegenerative disease and disability in the elderly; it is estimated to account for 60%-70% of all cases of dementia worldwide. The most relevant mechanistic hypothesis to explain AD symptoms is neurotoxicity induced by aggregated amyloid-β peptide (Aβ) and misfolded tau protein. These molecular entities are seemingly insufficient to explain AD as a multifactorial disease characterized by synaptic dysfunction, cognitive decline, psychotic symptoms, chronic inflammatory environment within the central nervous system (CNS), activated microglial cells, and dysfunctional gut microbiota. The discovery that AD is a neuroinflammatory disease linked to innate immunity phenomena started in the early nineties by several authors, including the ICC´s group that described, in 2004, the role IL-6 in AD-type phosphorylation of tau protein in deregulating the cdk5/p35 pathway. The "Theory of Neuroimmunomodulation", published in 2008, proposed the onset and progression of degenerative diseases as a multi-component "damage signals" phenomena, suggesting the feasibility of "multitarget" therapies in AD. This theory explains in detail the cascade of molecular events stemming from microglial disorder through the overactivation of the Cdk5/p35 pathway. All these knowledge have led to the rational search for inflammatory druggable targets against AD. The accumulated evidence on increased levels of inflammatory markers in the cerebrospinal fluid (CSF) of AD patients, along with reports describing CNS alterations caused by senescent immune cells in neuro-degenerative diseases, set out a conceptual framework in which the neuroinflammation hypothesis is being challenged from different angles towards developing new therapies against AD. The current evidence points to controversial findings in the search for therapeutic candidates to treat neuroinflammation in AD. In this article, we discuss a neuroimmune-modulatory perspective for pharmacological exploration of molecular targets against AD, as well as potential deleterious effects of modifying neuroinflammation in the brain parenchyma. We specifically focus on the role of B and T cells, immuno-senescence, the brain lymphatic system (BLS), gut-brain axis alterations, and dysfunctional interactions between neurons, microglia and astrocytes. We also outline a rational framework for identifying "druggable" targets for multi-mechanistic small molecules with therapeutic potential against AD.

Targeting neuroinflammation in Alzheimer's disease: from mechanisms to clinical applications

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Neuroinflammation of Microglial Regulation in Alzheimer's Disease: Therapeutic Approaches

Neuroinflammation in Alzheimer's Disease: Microglia, Molecular Participants and Therapeutic Choices.

Prevention and Treatment Strategies for Alzheimer's Disease: Focusing on Microglia and Astrocytes in Neuroinflammation

New Insights into Neuroinflammation Involved in Pathogenic Mechanism of Alzheimer's Disease and Its Potential for Therapeutic Intervention

Neuroinflammation in Alzheimer's disease: insights from peripheral immune cells

Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets

Tau and Neuroinflammation in Alzheimer’s Disease: Interplay Mechanisms and Clinical Translation

Gut Microbiota Mediates Neuroinflammation in Alzheimer’s Disease: Unraveling Key Factors and Mechanistic Insights

Revisiting the neuroinflammation hypothesis in Alzheimer's disease: a focus on the druggability of current targets

Tau and neuroinflammation in Alzheimer's disease: interplay mechanisms and clinical translation

Neuroinflammation, Its Role in Alzheimer’s Disease and Therapeutic Strategies

Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer's disease

Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer’s Disease Progression

Targeting Microglia in Alzheimer's Disease: Pathogenesis and Potential Therapeutic Strategies

Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer's Disease Progression

Neuroimmune Mechanisms Underlying Alzheimer's disease: Insights into central and peripheral immune cell crosstalk

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease

Alzheimer's Disease: From Immune Homeostasis to Neuroinflammatory Condition